

Helen A Petousis-Harris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/525798/publications.pdf>

Version: 2024-02-01

58
papers

1,223
citations

430754

18
h-index

395590

33
g-index

59
all docs

59
docs citations

59
times ranked

1428
citing authors

#	ARTICLE	IF	CITATIONS
1	Influences on Pregnant Women's and Health Care Professionals' Behaviour Regarding Maternal Vaccinations: A Qualitative Interview Study. <i>Vaccines</i> , 2022, 10, 76.	2.1	15
2	Increasing Uptake of Maternal Pertussis Vaccinations through Funded Administration in Community Pharmacies. <i>Vaccines</i> , 2022, 10, 150.	2.1	9
3	An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhoea in Adolescents in the Northern Territory, Australia—Study Protocol. <i>Vaccines</i> , 2022, 10, 309.	2.1	3
4	Recommendation to take a holistic view of the dynamic pathogenic pneumococcal environment. <i>Clinical Infectious Diseases</i> , 2022, , .	2.9	1
5	Methodological frontiers in vaccine safety: qualifying available evidence for rare events, use of distributed data networks to monitor vaccine safety issues, and monitoring the safety of pregnancy interventions. <i>BMJ Global Health</i> , 2021, 6, e003540.	2.0	8
6	Impact of rotavirus vaccine on paediatric rotavirus hospitalisation and intussusception in New Zealand: A retrospective cohort study. <i>Vaccine</i> , 2020, 38, 1730-1739.	1.7	4
7	Assessing the Safety of COVID-19 Vaccines: A Primer. <i>Drug Safety</i> , 2020, 43, 1205-1210.	1.4	34
8	Impact of antivaccination campaigns on health worldwide: lessons for Australia and the global community. <i>Medical Journal of Australia</i> , 2020, 213, 300.	0.8	1
9	Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019. <i>Vaccine</i> , 2020, 38, 4362-4373.	1.7	46
10	Global landscape analysis of no-fault compensation programmes for vaccine injuries: A review and survey of implementing countries. <i>PLoS ONE</i> , 2020, 15, e0233334.	1.1	27
11	A Qualitative Study of Views and Experiences of Women and Health Care Professionals about Free Maternal Vaccinations Administered at Community Pharmacies. <i>Vaccines</i> , 2020, 8, 152.	2.1	18
12	Progress Toward a Global Vaccine Data Network. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 1023-1025.	1.1	4
13	Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection. <i>New Zealand Medical Journal</i> , 2020, 133, 112-118.	0.5	7
14	Pneumococcal Conjugate Vaccines Turning the Tide on Inequity: A Retrospective Cohort Study of New Zealand Children Born 2006–2015. <i>Clinical Infectious Diseases</i> , 2019, 68, 818-826.	2.9	16
15	Reply to "Comment on Effectiveness of a Group B Outer Membrane Vesicle Meningococcal Vaccine in Preventing Hospitalization from Gonorrhoea in New Zealand: A Retrospective Cohort Study, <i>Vaccines</i> , 2019, 1, 5; doi:10.3390/vaccines7010005". <i>Vaccines</i> , 2019, 7, 32.	2.1	1
16	Pertussis Vaccination Failure in the New Zealand Pediatric Population: Study Protocol. <i>Vaccines</i> , 2019, 7, 65.	2.1	0
17	A Retrospective Cohort Study of Safety Outcomes in New Zealand Infants Exposed to Tdap Vaccine in Utero. <i>Vaccines</i> , 2019, 7, 147.	2.1	12
18	Exploitation of <i>Neisseria meningitidis</i> Group B OMV Vaccines Against <i>N. gonorrhoeae</i> to Inform the Development and Deployment of Effective Gonorrhoea Vaccines. <i>Frontiers in Immunology</i> , 2019, 10, 683.	2.2	30

#	ARTICLE	IF	CITATIONS
19	Comparison of vaccination coverage of four childhood vaccines in New Zealand and New York State. <i>Journal of Paediatrics and Child Health</i> , 2019, 55, 781-788.	0.4	2
20	Effectiveness of a Group B Outer Membrane Vesicle Meningococcal Vaccine in Preventing Hospitalization from Gonorrhoea in New Zealand: A Retrospective Cohort Study. <i>Vaccines</i> , 2019, 7, 5.	2.1	43
21	Author reply to VA-MENGOC-BC cross-protection (2018HV0022). <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1069-1069.	1.4	0
22	Pitfalls of the healthy vaccinee effect – Authors' reply. <i>Lancet</i> , The, 2018, 391, 123-124.	6.3	0
23	Impact of meningococcal group B OMV vaccines, beyond their brief. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1058-1063.	1.4	46
24	Pertussis Immunisation in Pregnancy Safety (PIPS) Study: A retrospective cohort study of safety outcomes in pregnant women vaccinated with Tdap vaccine. <i>Vaccine</i> , 2018, 36, 5173-5179.	1.7	49
25	Age-specific effectiveness following each dose of acellular pertussis vaccine among infants and children in New Zealand. <i>Vaccine</i> , 2017, 35, 177-183.	1.7	19
26	Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. <i>Lancet</i> , The, 2017, 390, 1603-1610.	6.3	303
27	Infant outcomes after exposure to Tdap vaccine in pregnancy: an observational study. <i>BMJ Open</i> , 2016, 6, e009536.	0.8	50
28	Safety of Tdap vaccine in pregnant women: an observational study. <i>BMJ Open</i> , 2016, 6, e010911.	0.8	38
29	Cherry picked case reports are not scientific evidence in the face of large clinical and epidemiological studies. <i>Clinical Rheumatology</i> , 2016, 35, 837-838.	1.0	0
30	Proposed HPV vaccination syndrome is unsubstantiated. <i>Clinical Rheumatology</i> , 2016, 35, 833-834.	1.0	10
31	Factors associated with reported pain on injection and reactogenicity to an OMV meningococcal B vaccine in children and adolescents. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1872-1877.	1.4	10
32	An investigation of three injections techniques in reducing local injection pain with a human papillomavirus vaccine: A randomized trial. <i>Vaccine</i> , 2013, 31, 1157-1162.	1.7	12
33	Human papillomavirus vaccination in Auckland: Reducing ethnic and socioeconomic inequities. <i>Vaccine</i> , 2012, 31, 84-88.	1.7	16
34	Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: The importance of routine active safety surveillance. <i>Vaccine</i> , 2012, 30, 4945-4952.	1.7	21
35	Measuring disparities in immunisation coverage among children in New Zealand. <i>Health and Place</i> , 2012, 18, 1217-1223.	1.5	11
36	What contributes to delays? The primary care determinants of immunisation timeliness in New Zealand. <i>Journal of Primary Health Care</i> , 2012, 4, 12.	0.2	17

#	ARTICLE	IF	CITATIONS
37	Early connections: effectiveness of a pre-call intervention to improve immunisation coverage and timeliness. <i>Journal of Primary Health Care</i> , 2012, 4, 189.	0.2	5
38	What contributes to delays? The primary care determinants of immunisation timeliness in New Zealand. <i>Journal of Primary Health Care</i> , 2012, 4, 12-20.	0.2	3
39	Fever following administration of two inactivated influenza vaccines—A survey of parents of New Zealand infants and children 5 years of age and under. <i>Vaccine</i> , 2011, 29, 2933-2937.	1.7	10
40	Back to Back: Saturated fat has been unfairly demonised: Yes. <i>Journal of Primary Health Care</i> , 2011, 3, 317.	0.2	3
41	Primary care practice and health professional determinants of immunisation coverage. <i>Journal of Paediatrics and Child Health</i> , 2011, 47, 541-549.	0.4	11
42	Saturated fat has been unfairly demonised: yes. <i>Journal of Primary Health Care</i> , 2011, 3, 317-9.	0.2	0
43	Fact or fallacy? Immunisation arguments in the New Zealand print media. <i>Australian and New Zealand Journal of Public Health</i> , 2010, 34, 521-526.	0.8	7
44	Factors associated with immunisation coverage and timeliness in New Zealand. <i>British Journal of General Practice</i> , 2010, 60, e113-e120.	0.7	24
45	Immunization champions: Characteristics of general practitioners associated with better immunization delivery. <i>Hum Vaccin</i> , 2009, 5, 403-411.	2.4	6
46	Seize the moments: missed opportunities to immunize at the family practice level. <i>Family Practice</i> , 2009, 26, 275-278.	0.8	19
47	Recruitment of practices in primary care research: the long and the short of it. <i>Family Practice</i> , 2009, 26, 128-136.	0.8	43
48	The cost of immunising at the general practice level. <i>Journal of Primary Health Care</i> , 2009, 1, 286.	0.2	8
49	The use and misuse of media headlines: lessons from the MeNZB immunisation campaign. <i>New Zealand Medical Journal</i> , 2009, 122, 22-7.	0.5	6
50	Determining immunisation coverage rates in primary health care practices: A simple goal but a complex task. <i>International Journal of Medical Informatics</i> , 2008, 77, 477-485.	1.6	12
51	Vaccine injection technique and reactogenicity—Evidence for practice. <i>Vaccine</i> , 2008, 26, 6299-6304.	1.7	53
52	MeNZB, a vaccine and epidemic control: When do you stop vaccinating?. <i>Vaccine</i> , 2008, 26, 5899-5904.	1.7	17
53	Immunization in the Print Media—Perspectives Presented by the Press. <i>Journal of Health Communication</i> , 2007, 12, 759-770.	1.2	16
54	Follow-up of MMR Vaccination Status in Children Referred to a Pediatric Immunization Clinic on Account of Egg Allergy. <i>Hum Vaccin</i> , 2005, 1, 118-122.	2.4	12

#	ARTICLE	IF	CITATIONS
55	Family practice nurse views on barriers to immunising children. <i>Vaccine</i> , 2005, 23, 2725-2730.	1.7	39
56	The New Zealand national immunisation hotlineâ€”what are callers seeking?. <i>Vaccine</i> , 2005, 23, 5038-5044.	1.7	2
57	Family physician perspectives on barriers to childhood immunisation. <i>Vaccine</i> , 2004, 22, 2340-2344.	1.7	39
58	Needle angle when giving i.m. vaccinations. <i>Nursing Praxis in New Zealand</i> , 2002, 18, 52-3.	0.2	1